📅 PUBMED DAILY TRIAGE — 2026-06-03

Window: 2026-06-02T09:00:00Z → 2026-06-03T09:00:00Z (CRDT) Topics scanned: 10 | Articles reviewed: ~80 unique candidates | Candidates evaluated: 20 classified High priority: 5 | Standard: 13 | Low/archive: 2 | Unsolicited finds: 1 Run status: ✅ SUCCESS

🔴🟠 HIGH PRIORITY (8+) — Best Finds by Topic

Early Cancer Detection (ctDNA / cfDNA)

TR-2026-06-03-001 / PMID 42230944 · Cell-free DNA methylation biomarkers for the early detection and tumor burden monitoring of gastric cancer · 8/10 🔴 EARLY_CANCER_DETECTION → cfDNA methylation GCML-score (13 DMRs) achieves AUC 0.95-0.99 across training/internal validation and 0.82 in external validation for early gastric cancer, with dynamic monitoring of tumor burden during neoadjuvant chemotherapy (NPJ Precision Oncology, n=171 GC + 114 controls, 2 Chinese centers).

AI/ML in Clinical Diagnostics and Imaging

TR-2026-06-03-002 / PMID 42230928 · Predicting diffusion-FLAIR mismatch from B1000 and ADC without FLAIR: A deep learning-based approach · 8/10 🟢 NEAR_TERM_IMPLEMENTABLE → Multi-center DL model achieves AUROC 0.92 on external validation (vs human expert 0.82, p<0.001) for acute stroke FLAIR mismatch assessment without requiring FLAIR sequence — addresses critical clinical bottleneck (Sci Rep, n=2369+679, Korean multi-center).

TR-2026-06-03-003 / PMID 42230774 · Deep learning prediction of pathological complete response in breast cancer using Mamba architecture · 8/10 🟢 NEAR_TERM_IMPLEMENTABLE → Novel Mamba-architecture AI model (MCEN) predicts pCR after neoadjuvant chemotherapy in breast cancer with AUROC 0.923/0.78 training/validation and 0.761-0.809 across 4 external hospitals — strong multi-center validation supporting clinical readiness (NPJ Digital Medicine, n=1646, 5 Chinese hospitals).

Novel Therapeutics (Immunotherapy / CAR-T / Targeted)

TR-2026-06-03-004 / PMID 42229339 · Comparative efficacy of tarlatamab and second-line therapies in extensive-stage small cell lung cancer: A network meta-analysis · 8/10 🟠 NOVEL_TREATMENT → Bayesian NMA confirms tarlatamab (anti-DLL3 BiTE) provides significantly better OS vs ALL available 2L ES-SCLC treatments including platinum rechallenge (HR 0.50-0.62), supporting new SOC status — ⚠️ NOTE: Amgen-sponsored study (Lung Cancer journal, Phase 3 DeLLphi-304 data).

TR-2026-06-03-005 / PMID 42230788 · Hallmarks and correlates of effective adoptive cell immunotherapy for cancer · 8/10 🟠 NOVEL_TREATMENT → Landmark review by Rosenberg/NCI Surgery Branch in Nature Reviews Immunology synthesizes TIL and TCR-T cell therapy evidence (including FDA-approved lifileucel and afami-cel), identifies CD39+ TIL as key biomarker of response, and outlines next-generation ACT strategies using immunogenomics + genome editing — defining field reference.

🟢⚪ STANDARD (5-7) — Top by Topic

Hematologic Malignancies

• TR-2026-06-03-008 / PMID 42227430 · MYD88 L265P cfDNA ddPCR monitoring in 158 treatment-naive DLBCL · 6/10 · Diagnostics/Liquid Biopsy

Early Cancer Detection (ctDNA / cfDNA)

• TR-2026-06-03-006 / PMID 42226668 · Dynamic PNI + KRAS ctDNA in localized PDAC (n=127); combined low PNI+ctDNA HR 3.64 · 7/10 · Early Detection
• TR-2026-06-03-012 / PMID 42228147 · Methylated BCAT1/IKZF1 ctDNA for CRC treatment monitoring; 100% ctDNA reduction in responders vs 0.13% in non-responders · 5/10 · Diagnostics
• TR-2026-06-03-014 / PMID 42230504 · cfDNA methylation (RARB/ZNF260) predicts lung cancer risk in COPD patients (n=26); 23% developed lung cancer · 5/10 · Early Detection

AI/ML in Clinical Diagnostics and Imaging

• TR-2026-06-03-010 / PMID 42230902 · SKELEX foundation model (1.2M MSK radiographs), 12 downstream tasks, bone tumor anomaly localization · 7/10 · Diagnostics
• TR-2026-06-03-015 / PMID 42230912 · AI LLMs (GPT-4o, Grok 3, Claude Sonnet 4, Gemini 2.5 Flash) vs dermatologists for nail disorders: AI 25-35% vs 70-80% accuracy · 6/10 · Diagnostics
• TR-2026-06-03-018 / PMID 42230969 · ClotIA SAM2-based FM for PE segmentation; DSC 0.83, BCV correlation r=0.995 · 6/10 · Diagnostics
• TR-2026-06-03-017 / PMID 42230748 · ML for BCG failure prediction in NMIBC (n=1524, Japan); feasibility confirmed, clinical utility limited by class imbalance · 5/10 · Diagnostics

Precision Oncology and Genomic Medicine

• TR-2026-06-03-011 / PMID 42230482 · Multi-omics review of metastatic PPGL (rare neuroendocrine tumor): ATRX/TERT, TMB, MSI, immunosuppressive TME · 5/10 · Genomics

Cardiovascular-Metabolic

• TR-2026-06-03-016 / PMID 42230805 · Aprocitentan (dual ET antagonist) in resistant HTN+CKD: benefits vs fluid retention trade-off, SGLT2i combo proposed · 5/10 · Treatment Innovation

Rare Diseases

• TR-2026-06-03-007 / PMID 42229223 · Canadian HoFH Registry (n=67): 20.9% MACE despite novel therapies; LDL-C median 13.53 mmol/L · 7/10 · Prevention/Rare Disease
• TR-2026-06-03-013 / PMID 42229093 · 3 novel mutations in Bernard-Soulier syndrome (GP9, GP1BA genes) in Iranian patients · 5/10 · Diagnostics

💡 UNSOLICITED FINDS

TR-2026-06-03-009 / PMID 42230412 · Traction-assisted vs conventional ESD for colorectal lesions · 7/10 · NEAR_TERM_IMPLEMENTABLE → Meta-analysis of 10 RCTs (n=1008): TA-ESD reduces procedure time by ~19 min and improves resection speed; borderline intraoperative perforation reduction (RR 0.46). Relevant to colorectal cancer early detection/prevention pipeline. (Techniques in Coloproctology)

📊 TODAY'S BREAKDOWN

By research category:

• Diagnostics: 9
• Early Detection: 4
• Treatment Innovation: 4
• Genomics/Precision Medicine: 2
• Prevention: 1
• Public Health: 1 (LOW)

By evidence maturity:

• Validated: 5 (TR-001 thru 005, TR-007, TR-016)
• Exploratory: 12
• (No Potentially Practice-Changing assigned — triage stage only)

By watchlist topic (reviewed / kept HIGH or STANDARD / highest score):

*TR-001 also matches Precision Oncology (dual-topic)

By source type: peer_reviewed: 20 | preprint: 0

Topics with zero 8+ articles this run:

• CBC-based diagnostics / ML
• Cardiovascular-metabolic
• Aging / longevity ← ZERO RELEVANT ARTICLES (both raw results were false positives)
• Rare diseases

🔧 RUN NOTES

⚠️ T8 (Aging/Longevity) — Zero Relevant Articles: Both raw results (PMID 42228237: psycholinguistics/prosody study; PMID 42226451: COVID-19 healthcare disparities) were false positives due to NCBI's broad MeSH expansion of "aged" and "humans" terms. This topic has now produced 0 relevant articles in the 1-day window. Recommended fix: add AND ("aging"[MeSH:noexp] OR "longevity"[MeSH] OR "cellular senescence"[MeSH] OR senolytic OR "epigenetic clock") as hard requirement.

⚠️ T2 (CBC/ML) — Continued Noise Problem: 21 raw results but 10-article review yielded only 1 marginally relevant result (PE segmentation reclassified to T4). NCBI's "hematology" term expansion matches hemorrhage, hematoma, blood in unrelated contexts. Recommended fix: Restrict to ("complete blood count"[tiab] OR "CBC parameters"[tiab] OR "blood cell morphology"[tiab]) AND (machine learning[MeSH] OR deep learning[MeSH]).

⚠️ T6 (Novel Therapeutics) — Volume/Noise: 98 raw results; top 10 included chitosan nanoparticle in-vitro study (PMID 42231018, discarded). CAR-T access letter (PMID 42230960) excluded by publication type rule.

Tarlatamab COI Note: PMID 42229339 NMA is Amgen-sponsored — all corresponding authors are Amgen employees or Analysis Group (paid Amgen consultant). Downstream pipeline should weight this limitation in evidence grading.

Window expansion: NOT triggered (≥5 relevant records found across topics).

Rolling 7-day view (from state): T2 (CBC/ML) had broken its 4-run streak yesterday — today again 0 pure CBC/ML articles. T8 now 3+ consecutive runs with 0 relevant aging/longevity articles.